Current drugs are antibiotics targeting ribosomal RNA (rRNA), such as the synthetic oxazolidinone linezolid that acts by binding a highly structured pocket, and the very recent Roche and PTC Therapeutics’ risdiplam, used in the treatment of spinal muscular atrophy (SMA), which acts by stabilising the interaction between an RNA splice site and a small nuclear ribonucleoprotein (snRNP) (Sheridan, 2021). Here, LSM2 is linked to spinal muscular atrophy.